In addition to the requirements of an efficient labeling procedure and a full chemical characterization, further considerations for clinical translation include: high concentration within the tumor (% ID/g); high binding specificity determined by the PSMA+-to-PSMA− cell uptake ratio; longer retention in PSMA+ tumor site versus the kidney; and low liver and gastrointestinal uptake. This evidence concerns the gene FOLH1 and neoplasm.